- Amarin (NASDAQ:AMRN): Q4 Non-GAAP EPS of $0.04 beats by $0.04; GAAP EPS of $0.01 beats by $0.02.
- Revenue of $167.25M (+16.7% Y/Y) beats by $3.04M.
- The Co. received positive CHMP Opinion for VAZKEPA® in Europe and continue to advance commercial launch plans for Europe.
- Ended 2020 with $563.4M in total cash and investments and no debt.
- Shares +0.68% PM.
- Press Release
Amarin EPS beats by $0.04, beats on revenue
Recommended For You
About AMRN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| AMRN | - | - |
| Amarin Corporation plc | ||